Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 01:15PM GMT
Release Date Price: $18.57 (-2.57%)
Unidentified Analyst

Good morning, and thank you for joining us today. My name is [Andrew Lang], and I'm an analyst in JPMorgan's health care group.

Before I introduce you to our presenters today, I want to call your attention to the blue ask a question button on your screen. This is where you'll submit questions that will be addressed at the end during the Q&A session.

With that, I am pleased to introduce you to the Syndax team here today. Briggs Morrison, CEO; Michael Metzger, President and COO; and Anjali Ganguli, CBO. I know they're very excited to tell you a little bit more about their story. So we'll turn it over to them.

Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Great. Thank you so much, Andrew, and welcome and thank you to those of you joining us on the line this morning for a summary of our current corporate priorities as we strive to realize a future in which people with cancer live longer and better than ever before.

I'm Briggs Morrison, CEO of Syndax. This call is being accompanied by a slide

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot